论文部分内容阅读
We conducted an open- labeled clinical trial of interferon beta1b (IFNB) treatment in 20 patients with primary progressive multiple sclerosis (PPMS) and longitudinally monitored autoantibodies against double- stranded DNA (dsDNA), thyroid peroxidase (TPO), myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), synapsin and S- 100B. Before treatment, one patient had elevated TPO antibodies, four patients had elevated antibodies against S- 100B, two patients against MOG or synapsin and one patient against MBP. In two patients we observed a continuous increase of dsDNA or TPO antibodies above the normal range. This rise paralleled IFNB treatment. In addition, 11 of 20 patients developed neutralizing antibodies against IFNB. There was no increase of autoantibodies directed against central nervous system antigens. Like patients with relapsing remitting or secondary progressive multiple sclerosis, PPMS patients may be at risk of an autoimmune response during IFNB treatment.
We conducted an open-labeled clinical trial of interferon beta 1b (IFNB) treatment in 20 patients with primary progressive multiple sclerosis (PPMS) and longitudinally monitored autoantibodies against double-stranded DNA (dsDNA), thyroid peroxidase (TPO), myelin basic protein ), myelin oligodendrocyte glycoprotein (MOG), synapsin and S-100B. Before treatment, one patient had elevated elevated antibodies against S-100B, two patients against MOG or synapsin and one patient against MBP. In two patients This addition paralleled IFNB treatment. In addition, 11 of 20 patients developed neutralizing antibodies against IFNB. There was no increase of autoantibodies directed against central nervous system antigens. Like patients with relapsing remitting or secondary progressive multiple sclerosis, PPMS patients may be at risk of an autoimmune response during IFNB treatment.